Enbrel (Rheumatoid Arthritis) Forecast and Market Analysis




$ 3495

In Stock

Enbrel (Rheumatoid Arthritis) Forecast and Market Analysis


GlobalData has released its new PharmaPoint Drug Evaluation report, Enbrel (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lillys anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZs SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market. Amgens Enbrel (etanercept) is a soluble TNF-receptor fusion protein used for the treatment of moderate to severe active RA patients who are unresponsive to one or more DMARDs. Enbrel is a leading biologic agent and is approved for multiple immunological indications including psoriasis and ankylosing spondylitis. Enbrel is a bivalent p75 receptor linked to the Fc portion of human IgG. Enbrel binds to lymphotoxin and TNF-alpha, blocking its interaction with cell surface TNF receptors, thus preventing synovial inflammation.


  • Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Enbrel (etanercept) including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Enbrel (etanercept) for the top ten countries from 2011 to 2022.
  • Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan, India, China and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Enbrel (etanercept) performance
  • Obtain sales forecast for Enbrel (etanercept) from 2011 to 2022 in (the US, France, Germany, the UK, Italy, Spain, Japan, India, China and Australia)